Novocure's TTFields Therapy Shows Positive Results in Phase 2 Trial for Metastatic Pancreatic Cancer

Novocure reported positive results from the Phase 2 PANOVA-4 trial of TTFields therapy in combination with atezolizumab and gem/nab-pac as a first-line treatment for metastatic pancreatic ductal adenocarcinoma. The trial met its primary endpoint, achieving a statistically significant improvement in disease control rate compared to a historical control. Secondary endpoints included objective response rate and overall survival, with ORR at 34.6% and median OS at 9.7 months. The company plans to evaluate the full results as it advances TTFields therapy for metastatic pancreatic cancer.